Who are Voluven (HES 130/0.4)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hyperoncotic Albumin 20%, Human Albumin (colloid), Albumin administration, Isooncotic Albumin 5%, Hydroxyethylstarch 130/0,4, Intravenous albumin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/voluven-hes-130-0-4.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Voluven (HES 130/0.4) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Voluven (HES 130/0.4) (Voluven (HES 130/0.4)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Colloid volume expander. Area: Cardiovascular.

phase 3 Colloid volume expander Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Voluven (HES 130/0.4) (Voluven (HES 130/0.4)) — Sangart. Voluven (HES 130/0.4) is a colloid volume expander used to increase blood volume.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Voluven (HES 130/0.4) TARGET	Voluven (HES 130/0.4)	Sangart	phase 3	Colloid volume expander
Hyperoncotic Albumin 20%	Hyperoncotic Albumin 20%	Insel Gruppe AG, University Hospital Bern	marketed	Colloid volume expander
Human Albumin (colloid)	Human Albumin (colloid)	The University of Texas Health Science Center, Houston	marketed	Colloid volume expander
Albumin administration	Albumin administration	Rennes University Hospital	marketed	Colloid volume expander
Isooncotic Albumin 5%	Isooncotic Albumin 5%	Insel Gruppe AG, University Hospital Bern	marketed	Colloid volume expander
Hydroxyethylstarch 130/0,4	Hydroxyethylstarch 130/0,4	Rigshospitalet, Denmark	marketed	Synthetic colloid volume expander
Intravenous albumin	Intravenous albumin	Hamilton Health Sciences Corporation	phase 3	Colloid volume expander / Plasma protein fraction

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Colloid volume expander class)

Insel Gruppe AG, University Hospital Bern · 2 drugs in this class
Asian Institute of Gastroenterology, India · 1 drug in this class
Rennes University Hospital · 1 drug in this class
Sangart · 1 drug in this class
The University of Texas Health Science Center, Houston · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Voluven (HES 130/0.4) — Competitive Intelligence Brief. https://druglandscape.com/ci/voluven-hes-130-0-4. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab